<?xml version="1.0" encoding="UTF-8"?>
<p>Over the past three decades, archived HIV samples have allowed commercial and academic researchers to develop and evaluate multiple new HIV assays and HIV diagnostic strategies, including new approaches to measure and monitor HIV prevalence and incidence 
 <sup>
  <xref rid="ref-1" ref-type="bibr">1</xref>, 
  <xref rid="ref-2" ref-type="bibr">2</xref>
 </sup>. This has allowed us to achieve improved sensitivity and specificity of assays with reduced time to detect infection following HIV acquisition 
 <sup>
  <xref rid="ref-3" ref-type="bibr">3</xref>– 
  <xref rid="ref-8" ref-type="bibr">8</xref>
 </sup>, attain an increased range of incidence and prognostic biomarkers 
 <sup>
  <xref rid="ref-9" ref-type="bibr">9</xref>– 
  <xref rid="ref-11" ref-type="bibr">11</xref>
 </sup>, advance techniques for identification of diverse HIV genotypes and recombinant viruses as well as prediction of drug resistance 
 <sup>
  <xref rid="ref-12" ref-type="bibr">12</xref>– 
  <xref rid="ref-18" ref-type="bibr">18</xref>
 </sup>, and automate and increase throughput of diagnostic platforms 
 <sup>
  <xref rid="ref-19" ref-type="bibr">19</xref>, 
  <xref rid="ref-20" ref-type="bibr">20</xref>
 </sup>. Through these enhanced strategies we have not only broadened the range of potential specimen types that can be used in diagnostic and incidence testing 
 <sup>
  <xref rid="ref-21" ref-type="bibr">21</xref>– 
  <xref rid="ref-23" ref-type="bibr">23</xref>
 </sup>, but we have also increased the settings in which testing occurs 
 <sup>
  <xref rid="ref-24" ref-type="bibr">24</xref>, 
  <xref rid="ref-25" ref-type="bibr">25</xref>
 </sup> and improved estimates of infection timing 
 <sup>
  <xref rid="ref-26" ref-type="bibr">26</xref>, 
  <xref rid="ref-27" ref-type="bibr">27</xref>
 </sup>.
</p>
